Skip to content
Anthim, Nyxthracis (previously obiltoxaximab sfl)(obiltoxaximab)
Anthim, Nyxthracis (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
immune system diseasesD007154
Trade Name
FDA
EMA
Anthim
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Obiltoxaximab
Tradename
Proper name
Company
Number
Date
Products
AnthimobiltoxaximabElusys TherapeuticsN-125509 RX2016-03-18
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
anthimBiologic Licensing Application2021-01-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anthrax—D000881A22
crohn diseaseEFO_0000384D003424K50
graft vs host disease—D006086D89.81
Agency Specific
FDA
EMA
Expiration
Code
obiltoxaximab, Anthim, Elusys Therapeutics, Inc.
2123-03-18Orphan excl.
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J06: Immune sera and immunoglobulins
— J06B: Immunoglobulins
— J06BC: Antibacterial monoclonal antibodies
— J06BC04: Obiltoxaximab
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnthraxD000881A222——1—3
Bacterial infectionsD001424A49———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOBILTOXAXIMAB
INNobiltoxaximab
Description
Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1351337-07-9
RxCUI—
ChEMBL IDCHEMBL3544926
ChEBI ID—
PubChem CID—
DrugBankDB05336
UNII ID29Z5DNL48C (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 191 documents
View more details
Safety
Black-box Warning
Black-box warning for: Anthim
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,247 adverse events reported
View more details